About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Domain Therapeutics to start clinical trials of solid tumor treatment

Nucleome Therapeutics raises £37.5M to deliver precision medicines

Empyrean Neuroscience launches with $22M to target CNS disorders

EditForce creates U-to-C RNA-editing technology

Emergex develops vaccine for smallpox and monkeypox

Gene activity could help identify risk of kidney cancer spreading

ADVERTISEMENT

Ophthalmology biopharma company Oculis combines with EBAC

Amgen joining Evotec and TIAP to boost Canadian life science companies

Kira Pharmaceuticals gets approval for paroxysmal nocturnal hemoglobinuria study

Positive results from Milestone Pharmaceuticals’ phase 3 PSVT trial

Clinical Microbiomics acquires MS-Omics

Italian study shows CRISPR/Cas9 deletion of Interleukin-30 reduces prostate cancer growth

ADVERTISEMENT